Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil

The prevalence of obesity is increasing, resulting in an increase in the number of surgeries performed to treat obesity and diseases induced by obesity. The associated comorbidities as well as the pharmacokinetic and pharmacodynamic changes that occur in obese patients make it difficult to control t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Tae Kyun Kim
Formato:	article
Lenguaje:	EN
Publicado:	Korean Society of Anesthesiologists 2021
Materias:	cardiac output computer simulation ideal body weight metabolic clearance rate obesity pharmacokinetics Anesthesiology RD78.3-87.3
Acceso en línea:	https://doaj.org/article/7b76b3e79863478b84f3a66688f9be92
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7b76b3e79863478b84f3a66688f9be92
record_format	dspace
spelling	oai:doaj.org-article:7b76b3e79863478b84f3a66688f9be922021-11-30T23:47:49ZObesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil2005-64192005-756310.4097/kja.21345https://doaj.org/article/7b76b3e79863478b84f3a66688f9be922021-12-01T00:00:00Zhttp://ekja.org/upload/pdf/kja-21345.pdfhttps://doaj.org/toc/2005-6419https://doaj.org/toc/2005-7563The prevalence of obesity is increasing, resulting in an increase in the number of surgeries performed to treat obesity and diseases induced by obesity. The associated comorbidities as well as the pharmacokinetic and pharmacodynamic changes that occur in obese patients make it difficult to control the appropriate dose of anesthetic agents. Factors that affect pharmacokinetic changes include the increase in adipose tissue, lean body weight, extracellular fluid, and cardiac output associated with obesity. These physiological and body compositional changes cause changes in the pharmacokinetic and pharmacodynamic parameters. The increased central volume of distribution and alterations in the clearance of drugs affect the plasma concentration of propofol and remifentanil in the obese population. Additionally, obesity can affect pharmacodynamic properties, such as the 50% of maximal effective concentration and the effect-site equilibration rate constant (ke0). Conducting a simulation of target-controlled infusions based on pharmacokinetic and pharmacodynamic models that include patients that are obese can help clinicians better understand the pharmacokinetic and pharmacodynamic changes of anesthetic drugs associated with this population.Tae Kyun KimKorean Society of Anesthesiologistsarticlecardiac outputcomputer simulationideal body weightmetabolic clearance rateobesitypharmacokineticsAnesthesiologyRD78.3-87.3ENKorean Journal of Anesthesiology, Vol 74, Iss 6, Pp 478-487 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cardiac output computer simulation ideal body weight metabolic clearance rate obesity pharmacokinetics Anesthesiology RD78.3-87.3
spellingShingle	cardiac output computer simulation ideal body weight metabolic clearance rate obesity pharmacokinetics Anesthesiology RD78.3-87.3 Tae Kyun Kim Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil
description	The prevalence of obesity is increasing, resulting in an increase in the number of surgeries performed to treat obesity and diseases induced by obesity. The associated comorbidities as well as the pharmacokinetic and pharmacodynamic changes that occur in obese patients make it difficult to control the appropriate dose of anesthetic agents. Factors that affect pharmacokinetic changes include the increase in adipose tissue, lean body weight, extracellular fluid, and cardiac output associated with obesity. These physiological and body compositional changes cause changes in the pharmacokinetic and pharmacodynamic parameters. The increased central volume of distribution and alterations in the clearance of drugs affect the plasma concentration of propofol and remifentanil in the obese population. Additionally, obesity can affect pharmacodynamic properties, such as the 50% of maximal effective concentration and the effect-site equilibration rate constant (ke0). Conducting a simulation of target-controlled infusions based on pharmacokinetic and pharmacodynamic models that include patients that are obese can help clinicians better understand the pharmacokinetic and pharmacodynamic changes of anesthetic drugs associated with this population.
format	article
author	Tae Kyun Kim
author_facet	Tae Kyun Kim
author_sort	Tae Kyun Kim
title	Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil
title_short	Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil
title_full	Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil
title_fullStr	Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil
title_full_unstemmed	Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil
title_sort	obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil
publisher	Korean Society of Anesthesiologists
publishDate	2021
url	https://doaj.org/article/7b76b3e79863478b84f3a66688f9be92
work_keys_str_mv	AT taekyunkim obesityandanestheticpharmacologysimulationoftargetcontrolledinfusionmodelsofpropofolandremifentanil
_version_	1718406210816835584

Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil

Ejemplares similares